advanced pancreatic cancer
Conditions
Interventions
Theracurmin
placebo
Sponsors
Kyoto University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with histologically or cytologically comfirmed pancreatic cancer who have not received palliative chemotherapy 2. Age >/=20 3. ECOG performance status </=2 4. Adequate oral intake 5. Adequate organ and bone marrow function 6. Provided written informed consent
Exclusion criteria
Exclusion criteria: 1.Patients with active interstitial pneumonia or pulmonary fibrosis 2.Patients with digestive tract obstruction confirmed by imaging test 3.Patients with moderate or severe ascites /pleural effusion 4.Patients with uncontrollable diabetes mellitus, liver dysfunction, severe heart disease 5.Patients with serious infection 6.Patients with a history of severe drug allergy 7.Patients with other serious comorbid diseases 8.Patients with other advanced cancer 9.Pregnant women or patients who wish pregnant 10.Patients with mental diseases 11.Patients who are judged inappropriate for the entry into the study by the investigator
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| overall survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life (QOL) score, Time to Treatment Failure, response rate, safety | — |
Countries
Japan
Contacts
Public ContactKanai Masashi
Kyoto University Hospital Department of Clinical Oncology and Pharmacogenomics
Outcome results
None listed